Pham Vi, Dong Maoqing, Wade John D, Miller Laurence J, Morton Craig J, Ng Hooi-Ling, Parker Michael W, Sexton Patrick M
Howard Florey Institute, The University of Melbourne, Victoria 3010, Australia.
J Biol Chem. 2005 Aug 5;280(31):28610-22. doi: 10.1074/jbc.M503272200. Epub 2005 Jun 1.
Fish-like calcitonins (CTs), such as salmon CT (sCT), are widely used clinically in the treatment of bone-related disorders; however, the molecular basis for CT binding to its receptor, a class II G protein-coupled receptor, is not well defined. In this study we have used photoaffinity labeling to identify proximity sites between CT and its receptor. Two analogues of the antagonist sCT(8-32) containing a single photolabile p-benzoyl-l-phenylalanine (Bpa) residue in position 8 or 19 were used. Both analogues retained high affinity for the CT receptor and potently inhibited agonist-induced cAMP production. The [Bpa(19)]sCT(8-32) analogue cross-linked to the receptor at or near the equivalent cross-linking site of the full-length peptide, within the fragment Cys(134)-Lys(141) (within the amino terminus of the receptor, adjacent to transmembrane 1) (Pham, V., Wade, J. D., Purdue, B. W., and Sexton, P. M. (2004) J. Biol. Chem. 279, 6720-6729). In contrast, proteolytic mapping and mutational analysis identified Met(49) as the cross-linking site for [Bpa(8)]sCT(8-32). This site differed from the previously identified cross-linking site of the agonist [Bpa(8)]human CT (Dong, M., Pinon, D. I., Cox, R. F., and Miller, L. J. (2004) J. Biol. Chem. 279, 31177-31182) and may provide evidence for conformational differences between interaction with active and inactive state receptors. Molecular modeling suggests that the difference in cross-linking between the two Bpa(8) analogues can be accounted for by a relatively small change in peptide orientation. The model was also consistent with cooperative interaction between the receptor amino terminus and the receptor core.
鱼类降钙素(CTs),如鲑鱼降钙素(sCT),在临床上被广泛用于治疗与骨骼相关的疾病;然而,CT与其受体(一种II类G蛋白偶联受体)结合的分子基础尚未明确。在本研究中,我们使用光亲和标记来确定CT与其受体之间的邻近位点。使用了拮抗剂sCT(8 - 32)的两种类似物,它们在第8位或第19位含有单个光不稳定的对苯甲酰-L-苯丙氨酸(Bpa)残基。两种类似物对CT受体均保持高亲和力,并能有效抑制激动剂诱导的cAMP产生。[Bpa(19)]sCT(8 - 32)类似物在全长肽的等效交联位点处或附近与受体交联,位于片段Cys(134)-Lys(141)内(在受体的氨基末端,与跨膜1相邻)(范,V.,韦德,J. D.,普渡,B. W.,和塞克斯顿,P. M.(2004年)《生物化学杂志》279,6720 - 6729)。相比之下,蛋白水解图谱分析和突变分析确定Met(49)为[Bpa(8)]sCT(8 - 32)的交联位点。该位点与先前确定的激动剂[Bpa(8)]人CT的交联位点不同(董,M.,皮农,D. I.,考克斯,R. F.,和米勒,L. J.(2004年)《生物化学杂志》279,31177 - 31182),可能为与活性和非活性状态受体相互作用之间的构象差异提供证据。分子建模表明,两种Bpa(8)类似物之间交联的差异可由肽方向的相对较小变化来解释。该模型也与受体氨基末端和受体核心之间的协同相互作用一致。